Protocol
Metabolic Reset
Sixteen-week 5-Amino-1MQ plus low-dose GLP-1 for insulin sensitivity and metabolic flexibility.
Why this stack
The rationale.
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that is upregulated in obese and insulin-resistant adipose tissue and drains both NAD+ and SAM pools — restoring those pools improves adipocyte metabolic flexibility and energy expenditure. Pairing it with a low, fixed semaglutide dose adds incretin-axis insulin sensitization and modest post-meal glucose control without pushing into the aggressive appetite-suppression range. Together they target metabolic-health markers (HOMA-IR, HbA1c, fasting glucose) more cleanly than either alone, and the low GLP-1 dose minimizes muscle-loss risk that aggressive GLP-1 titration carries.
The protocol
Dose, frequency, cycle.
- Dose
- 50,000mcg
- Frequency
- Daily
- Cycle
- 16 weeks on, 4 weeks off
- Timing
- oral morning fasted, 50 mg daily (note: this is mg, not mcg — entered here as 50000 mcg)
- Dose
- 250mcg
- Frequency
- 1×/week
- Cycle
- 16 weeks on, 4 weeks off
- Timing
- subq weekly, hold at the starter dose — this is metabolic, not weight-loss titration
Expected timeline
What to expect, when.
weeks 1-2: GLP-1 GI adaptation, mild appetite shift. weeks 3-6: fasting glucose trends down, post-meal glucose excursions blunt visibly on CGM if worn. weeks 7-12: HOMA-IR improvement, energy more stable across the day, fasted training tolerance up. weeks 13-16: HbA1c shifts measurably (typically -0.2 to -0.5 from baseline if elevated), waist circumference reduces modestly even without aggressive caloric deficit.
Monitoring markers
What to track.
- fasting glucose (weekly home meter or CGM)
- HbA1c (baseline, week 8, week 16)
- fasting insulin and HOMA-IR (baseline and week 16)
- lipid panel including triglycerides and ApoB
- hsCRP
- liver enzymes (ALT, AST) — 5-Amino-1MQ is hepatically processed
- resting heart rate
Contraindications
- personal or family history of medullary thyroid carcinoma
- MEN2 syndrome
- active or prior pancreatitis
- active liver disease or elevated liver enzymes
- pregnancy or attempt to conceive
- severe gastroparesis
- concurrent use of methylation-modulating drugs without prescriber review
Description
Protocol overview.
A metabolic-health-focused stack pairing 5-Amino-1MQ (an NNMT inhibitor that restores cellular NAD+/SAM pools and adipocyte metabolic flexibility) with a deliberately low semaglutide dose held below the typical weight-loss titration. The goal is insulin sensitivity and metabolic resilience, not aggressive weight loss.
Clone this protocol to your account.
Drop it onto your dashboard, pin doses to your weekly schedule, and let the daily-protocol screen tell you what to draw each morning. Reconstitution math, site rotation, and lab reminders come with it.